The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s calcium channel blocker market report forecasts the calcium channel blocker market size to grow to $18.60 Billion by 2027, with a CAGR (compound annual growth rate) of more than 6%.

Learn More On The Calcium Channel Blocker Market Report 2023 – https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report

Calcium Channel Blocker Market Size Forecast
The global calcium channel blocker market is expected to grow from $13.75 billion in 2022 to $14.66 billion in 2023 at a compound annual growth rate (CAGR) of 6.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global calcium channel blocker market size is expected to grow to $18.60 billion in 2027 at a CAGR of 6.1%.

North America held the largest calcium channel blocker market share.

Key Calcium Channel Blocker Market Driver ­– Increase In The Prevalence Rate Of Cardiovascular Diseases
According to a report published by the American Heart Association, a US-based organisation dedicated to the prevention and treatment of heart disease and stroke, cardiovascular disease (CVD) was responsible for approximately 19.1 million deaths worldwide in 2020. The age-adjusted death rate was 239.8 individuals per 100,000. 7354.1 per 100,000 was the age-adjusted prevalence rate. In 2020, the highest rates of CVD-related mortality were found in Eastern Europe and Central Asia. As a result, the rising frequency of cardiovascular disorders is propelling the calcium channel blocker market forward.

Request for A Sample Of The Global Calcium Channel Blocker Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9428&type=smp

Key Calcium Channel Blocker Market Trend – Product Innovation
To maintain their market position, major businesses in the calcium channel blockers market are focusing on producing innovative products. CMP Pharma, a US-based pharmaceutical manufacturing company, for example, developed Norliqva in June 2022, the first and only oral liquid solution of the besylate salt of amlodipine, a long-acting calcium channel blocker. Norliqva’s distinguishing feature is that it is an amlodipine liquid solution intended to treat hypertension in people aged 6 and up. Norliqva eliminates the problems and inconsistencies associated with crushing or synthesising amlodipine tablets, ensuring uniform dosage and bioequivalence. Norliqva is intended for a subset of individuals who need amlodipine but have swallowing problems or are unable to swallow.

Calcium Channel Blocker Market Segment
1) By Drug Class: Dihydropyridine, Benzothizepine, Phenylalkylamine, Other Drug Classes
2) By Disease Indications: Hypertension, Chest Pain, Arrhythmias
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users

Calcium Channel Blocker Market Major Players and Strategies
Major players in the calcium channel blocker market are Pfizer Inc., GSK Plc., Novartis AG, Bausch Health Companies Inc., Lupin Pharmaceuticals Inc., Zydus Group, Covis Pharma BV, Mylan NV, Glenmark Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Sofgen Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knoll Healthcare Private Limited, Sanofi S.A, and Clearsynth.

Azurity Pharmaceuticals Inc., a specialised pharmaceutical business based in the United States, paid an unknown sum for Arbour Pharmaceuticals LLC in September 2021. The acquisition builds a top firm that provides cutting-edge, high-value goods to meet the specific needs of people suffering from underserved conditions. Arbour Pharmaceuticals LLC is a specialised pharmaceutical firm established in the United States that specialises in calcium channel blocking medicines.

The Calcium Channel Blocker Global Market Report 2023 covers regional data on calcium channel blocker market size, calcium channel blocker market trends and drivers, opportunities, strategies, and calcium channel blocker market competitor analysis. The countries covered in the calcium channel blocker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Calcium channel blockers are drugs that inhibit calcium from entering the heart and blood vessel muscle cells. Calcium channel blockers are used to treat a wide range of conditions, including excessive blood pressure, angina, and irregular heartbeats.

View More Reports Related To The Calcium Channel Blocker Market –
Calcium Carbide Global Market Report 2023
Calcium Peroxide Global Market Report 2023
Anti-Hypertensive Drugs Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: